BPI-452080
- Generic Name
- BPI-452080
A Study of BPI-452080 in Subjects With Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Renal Cell CarcinomaSolid TumorVon Hippel-Lindau Disease
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 87
- Registration Number
- NCT05843305
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳Hunan Cancer Hospital, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath